8-K filing — PTC THERAPEUTICS, INC. (PTCT)
Filed: 2026-08-28 AccNo: 0001070081-26-000019 Size: 165 KB Item 1.01: Entry into a Material Definitive Agreement
Stocks · News reference
PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals
Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy for the enzyme
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.